TrialCancer2015

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.